{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:05:32Z","timestamp":1781327132371,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ck0106976"],"award-info":[{"award-number":["JP24ck0106976"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Central nervous system (CNS) relapse is an uncommon yet lethal event in patients with DLBCL. Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisolone (pola-R-CHP) is a standard of care for patients with untreated DLBCL. In patients with DLBCL at high risk of CNS relapse, the intrathecal (IT) administration of methotrexate and cytarabine is widely adopted for CNS prophylaxis; however, the optimal treatment is unclear. The aim of this multicenter randomized phase III trial is to confirm the superiority of high-dose methotrexate administered during early cycles of pola-R-CHP in addition to IT chemotherapy for patients with untreated DLBCL at high risk of CNS relapse. A total of 390 patients from 52 institutions will be enrolled across a 4-year period. The primary endpoint is progression-free survival. This trial was registered in the Japan Registry of Clinical Trials as jRCTs031230505 [https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCTs031230505].<\/jats:p>","DOI":"10.1093\/jjco\/hyaf202","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T13:10:30Z","timestamp":1764335430000},"page":"358-363","source":"Crossref","is-referenced-by-count":1,"title":["Protocol digest of a randomized phase III study of pola-R-CHP\/high-dose methotrexate\/IT vs. pola-R-CHP\/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER)"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7753-8712","authenticated-orcid":false,"given":"Yusuke","family":"Sano","sequence":"first","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6547-3181","authenticated-orcid":false,"given":"Kana","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mie University Graduate School of Medicine , 2-174 Edobashi, Tsu, Mie 514-8507 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-6489","authenticated-orcid":false,"given":"Motoko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Hematological Malignancies, Mie University Graduate School of Medicine , 2-174 Edobashi, Mie 514-8507,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3932-8084","authenticated-orcid":false,"given":"Senzo","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-31 Ariake, Koto-ku, Tokyo 135-8550 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Machida","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-9219","authenticated-orcid":false,"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine , 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center , 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi 460-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-0656","authenticated-orcid":false,"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-31 Ariake, Koto-ku, Tokyo 135-8550 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan Clinical Oncology Group Lymphoma Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2026031310015541200_ref1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the international lymphoma study group classification of non-Hodgkin\u2019s lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"2026031310015541200_ref2","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1002\/cam4.1805","article-title":"Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification","volume":"7","author":"Muto","year":"2018","journal-title":"Cancer Med"},{"key":"2026031310015541200_ref3","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026031310015541200_ref4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/annonc\/mdm073","article-title":"Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up","volume":"18","author":"Bjorkholm","year":"2007","journal-title":"Ann Oncol"},{"key":"2026031310015541200_ref5","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"key":"2026031310015541200_ref6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin\u2019s lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the southwest oncology group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026031310015541200_ref7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","article-title":"Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma","volume":"93","author":"El-Galaly","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026031310015541200_ref8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031310015541200_ref9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/bjh.14325","article-title":"Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement","volume":"175","author":"El-Galaly","year":"2016","journal-title":"Br J Haematol"},{"key":"2026031310015541200_ref10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00277-013-2003-y","article-title":"Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse","volume":"93","author":"Cao","year":"2014","journal-title":"Ann Hematol"},{"key":"2026031310015541200_ref11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1349-7006.2011.02139.x","article-title":"Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era","volume":"103","author":"Tomita","year":"2012","journal-title":"Cancer Sci"},{"key":"2026031310015541200_ref12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3109\/10428194.2014.931953","article-title":"Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone","volume":"56","author":"Tomita","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2026031310015541200_ref13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3109\/10428194.2014.946027","article-title":"Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the consortium for improving survival of lymphoma","volume":"56","author":"Lee","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2026031310015541200_ref14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejca.2016.12.029","article-title":"The number of extranodal sites assessed by PET\/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy","volume":"75","author":"El-Galaly","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026031310015541200_ref15","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.11406\/rinketsu.59.2146","article-title":"Revision of JSH guideline for tumors of hematopoietic and lymphoid tissues 2018: lymphoma","volume":"59","author":"Nagai","year":"2018","journal-title":"Rinsho Ketsueki"},{"key":"2026031310015541200_ref16","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","article-title":"First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial","volume":"29","author":"Vitolo","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026031310015541200_ref17","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma","volume":"111","author":"Cheah","year":"2014","journal-title":"Br J Cancer"},{"key":"2026031310015541200_ref18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/bjh.13194","article-title":"Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"168","author":"Ferreri","year":"2015","journal-title":"Br J Haematol"},{"key":"2026031310015541200_ref19","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1182\/bloodadvances.2020003947","article-title":"Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis","volume":"5","author":"Jeong","year":"2021","journal-title":"Blood Adv"},{"key":"2026031310015541200_ref20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41408-021-00506-3","article-title":"Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse","volume":"11","author":"Bobillo","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026031310015541200_ref21","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ajh.26181","article-title":"Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma","volume":"96","author":"Puckrin","year":"2021","journal-title":"Am J Hematol"},{"key":"2026031310015541200_ref22","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1093\/annonc\/mdx353","article-title":"Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial","volume":"28","author":"Gleeson","year":"2017","journal-title":"Ann Oncol"},{"key":"2026031310015541200_ref23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1470-2045(20)30059-0","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial","volume":"21","author":"Shimada","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026031310015541200_ref24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1182\/bloodadvances.2020002567","article-title":"A randomized phase 2\/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial","volume":"5","author":"Ohmachi","year":"2021","journal-title":"Blood Adv"},{"key":"2026031310015541200_ref25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2307\/2530299","article-title":"Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint","volume":"38","author":"Schoenfeld","year":"1982","journal-title":"Biometrics"},{"key":"2026031310015541200_ref26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/biomet\/70.3.659","article-title":"Discrete sequential boundaries for clinical-trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"2026031310015541200_ref27","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/sim.4780121516","article-title":"Applying Bayesian ideas in drug development and clinical trials","volume":"12","author":"Spiegelhalter","year":"1993","journal-title":"Stat Med"},{"key":"2026031310015541200_ref28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0197-2456(82)90022-8","article-title":"An aid to data monitoring in long-term clinical trials","volume":"3","author":"Halperin","year":"1982","journal-title":"Control Clin Trials"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/3\/358\/65926526\/hyaf202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/3\/358\/65926526\/hyaf202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:02:05Z","timestamp":1773410525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/3\/358\/8381868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2026,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf202","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,17]]}}}